<DOC>
	<DOCNO>NCT00861250</DOCNO>
	<brief_summary>The primary objective study determine rate molecular remission ( MolR ) assess ASO-RQ-PCR technique induction treatment bortezomib dexamethasone ( Vel/Dex ) prior high-dose therapy melphalan autologous stem cell transplantation ( HDT-ASCT ) , HDT-ASCT patient multiple myeloma .</brief_summary>
	<brief_title>Assessment Molecular Remission ASO-qPCR After Bortezomib-dexamethasone ( Vel/Dex ) Followed ASCT</brief_title>
	<detailed_description>HDT-ASCT far consider standard care younger patient multiple myeloma ( MM ) . Current evidence indicate quality response important prognostic factor long-term survival MM . There data molecular remission ( MolR ) determine sensitive technique , allele-specific-oligonucleotide - real-time quantitative - polymerase chain reaction ( ASO-RQ-PCR ) MM , data available molecular response bortezomib-based induction therapy follow HDT-ASCT . The main aim study determine molecular response rate ASCT follow bortezomib-based induction treatment compare historical control group conventional VAD induction treatment . A sensitivity ASO-RQ-PCR technique compare immunofixation immunophenotyping flow cytometry .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Symptomatic multiple myeloma Age 1865 year Written inform consent WHO performance status ≥ 2 , unless relate MM Severe cardiac dysfunction History hypotension Serious medical psychiatric illness Severe hepatic dysfunction Severe polyneuropathy ≥ grade 2 Active , uncontrolled infection Previously treat chemotherapy extensive radiotherapy MM Known HIV positivity Severe renal dysfunction need dialysis History active cancer past 5 year , except nonmelanoma skin cancer stage 0 cervical cancer Female patient pregnant nurse Male female patient reproductive potential practising effective mean contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Bortezomib plus dexamethasone induction therapy</keyword>
	<keyword>Autologous stem cell transplantation</keyword>
	<keyword>Molecular remission</keyword>
</DOC>